30 March 2022 Sydney, Australia

Updated Nyrada Investor Roadshow Presentation

Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation ahead of a domestic investor roadshow led by Nyrada CEO, James Bonnar, which is taking place during March and April 2022.

The presentation provides an overview of the Company's two lead drug development programs and an update on their progress as they advance towards Phase I first-in-human studies.

-ENDS-

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:
Laura Vize
Investor Relations Manager
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:
Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Investor Presentation

March & April 2022 | Sydney NSW

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Important Notice & Disclaimer

This presentation has been prepared by Nyrada Inc **(NYR** or **the Company**). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Company Overview

- Two lead drug development programs with significant therapeutic and commercial potential:
  - **Cholesterol-Lowering Program**
  - **Brain Injury Program**
- Preclinical studies delivering superior results
- Collaborations with world leading institutions, **Walter Reed Army Institute of Research (WRAIR)** and **UNSW Sydney**
- Funding secured to complete planned Phase I studies
- Commercially focused business model
- Experienced Board of Directors with impressive track record in biotech

Nyrada Leadership Team

- Nyrada operates under the direction of a board of international calibre
- Strong track record in finding and realising the value of biotech companies

Mr John Moore
Non-Executive Chairman

Dr Ian Dixon
Non-Executive Director

Christopher Cox
Non-Executive Director

Mr Peter Marks
Non-Executive Director

Mr Marcus Frampton
Non-Executive Director

Dr Rüdiger Weseloh
Non-Executive Director

James Bonnar
Chief Executive Officer

Scientific Advisory Board

Professor Gary Housley
Chair, M.Sc Ph.D

Chair in Physiology (UNSW) and founding Director of the Translational Neuroscience Facility.

Pioneered the science behind Nyrada's Brain Injury Program.



Professor David Burke
MD, DSc, AC

Professor of Neurology at Royal Prince Alfred Hospital and Sydney Medical School (USYD).



Professor Gilles Lambert
Ph.D

Professor in Cell Biology at University of La Réunion Medical School (France) and group leader, Inserm laboratory of Diabetes & Atherothrombosis of the University Hospital of La Réunion.

Professor Junichi Nabekura, Ph.D

Professor of Physiology and Neuroscience and Director General of the National Institute of Physiological Sciences, a leading research institution in Japan.



Dr. Jim Palmer
Ph.D

More than 30 years of experience in drug discovery programs targeting oncology, cardiovascular, inflammation, joint and bone disease, and infectious diseases.

Vision & Strategy

- To improve lives and offer hope through innovation
- Deliver novel treatments for diseases where:
  - There is unmet clinical need; or
  - Current treatments are suboptimal

Our strategy is to advance highly optimised drug candidates towards a **key value inflection point**, such as an efficacy signal, and **out-licence them early**, where the **risk reward** equation is **most favourable** for Nyrada shareholders


Nyrada
inc
Cholesterol-Lowering Program
ASX:NYR

High LDL Cholesterol and Cardiovascular Disease (CVD)

Problem and key statistics

Statins are suboptimal for 70% of patients and often poorly tolerated

- Statins reduce risk of CVD but ~1 in 5 patients are statin intolerant, a key reason treatment is discontinued[3]
- Intolerance symptoms include muscle pain, liver dysfunction, renal insufficiency, diabetes and eye conditions[4]

High LDL cholesterol a leading cause of CVD

CVD responsible for 1 in 4 deaths

Healthcare costs for CVD ~US$363B/year (US)[1]

62M US adults with high LDL cholesterol[2]

27M US adults take a statin drug[2]

19M unable to reach target despite statin treatment[2]

1 Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics - 2021 update: A report from the American Heart Association, 2021; average annual indirect and direct CVD related costs estimated for 2016-17.
2 Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin Lipidology. 2016
3 Management of Statin Intolerance in 2018: Still More Questions Than Answers, Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Am J Cardiovasc Drugs. 2018 Jun;18(3):157-173
4 Cai T, Abel L, Langford O, Monaghan G, Aronson J K, Stevens R J et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses, BMJ 2021

Nyrada’s Cholesterol-Lowering Program

- We are developing an oral PCSK9 inhibitor drug (taken as a pill) for the treatment of high LDL (bad) cholesterol levels in patients at risk of cardiovascular disease

- Nyrada’s drug would replace expensive and inconvenient injectable PCSK9 inhibitor drugs and could be taken on its own or in combination with a statin



Program Milestones

2H CY2020

JULY 2020

NYX-PCSK9i demonstrates equivalency to FDA approved Repatha® and Praluent®

DEC 2020

NYX-PCSK9i shows 57% reduction in total cholesterol[1]

1H CY2021

JAN 2021

NYX-PCSK9i well tolerated, lowers LDL cholesterol in a dose-dependent manner[1]

MAY 2021

Medicinal chemistry program reveals new potent drug candidates

JUN 2021

NYX-PCSK9i reduces total cholesterol by 65% when given in combination with a statin, outperforms Lipitor® (atorvastatin, Pfizer)[1]

2H CY2021

JUL 2021

US Patent & Trademark Office issue first patent for Nyrada's PCSK9i inhibitor technology

AUG 2021

NYX-PCSK9i mechanism of action confirmed following further exploratory analysis[1]

DEC 2021

Charles River Laboratories appointed to conduct preclinical studies in US

UPCOMING

CY 2022

Charles River Laboratories to conduct preclinical studies in 1H CY2022, Phase I first in human clinical trial to commence 2H CY2022

[1] *In vivo* study conducted in specialised mouse model (APOE*3-Leiden.CTP) genetically modified to mimic human-like characteristics concerning cholesterol metabolism and cardiovascular health.

Nyrada inc

Brain Injury Program

ASX:NYR

Global Market with Large Unmet Need - Brain Injury After TBI or Stroke

Nyrada is developing a neuroprotectant drug to reduce the impact of secondary brain injury in patients following a stroke or traumatic brain injury (TBI), which can occur following a motor vehicle accident, fall, or sporting injury.

TRAUMATIC BRAIN INJURY

Traumatic brain injury is a global problem affecting millions, yet there is **no FDA approved drug available** and treatment options are limited to neurosurgery and supportive care

2.8 million
TBIs in US[1]

4.1 million
TBIs in US, UK, Europe and Japan (2020)[2]

5.3 million
Americans living with post TBI disability[3]

STROKE

800,000 strokes
annually (US)[4]

One drug class for stroke
suitable to less than 15% of patients

5-Year Outcomes of Persons with TBI[5]



Data are US population estimates based on the TBIMS National Database. Data refer to people 16 years of age and older who received inpatient rehabilitation services for a primary diagnosis of TBI.

1 Brain Injury Alliance (Connecticut): http://www.biact.org/understanding-brain-injury/brain-injury-facts-statistics
2 Total TBIs in US, Germany, France, Italy, Spain, UK and Japan, Traumatic Brain Injury, Market Insight, Epidemiology and Market Forecast, DelveInsight, published January 2021
3 US Brain Injury Alliance: https://usbia.org/
4 US Centers for Disease Control and Prevention: https://www.cdc.gov/stroke/index.htm
5 'Moderate to Severe Traumatic is a Lifelong Condition', CDC publication available at: https://www.cdc.gov/traumaticbraininjury/pdf/moderate_to_severe_tbi_lifelong-a.pdf

Reducing Secondary Brain Injury After TBI or Stroke

First-ever drug to improve survivability and patient quality of life

- Treatment for secondary brain injury following TBI or Stroke
- Administered intravenously (TBI and Stroke) or intranasally (Concussion)
  - Prevent cell death
  - Attenuate damaged brain volume
  - Improve survivability, limit disability, improve quality of life
- In the US, UK, Europe and Japan alone, the size of the TBI market in 2020 was US$6.7 billion and estimated to grow at a CAGR of 5.54% between 2018–2030[1]
- Stroke market estimated to surpass US$3.5B by 2027[2]



[1] Traumatic Brain Injury, Market Insight, Epidemiology and Market Forecast, DelveInsight, published January 2021
[2] Coherent Market Insights press release dated 10 May 2021

Program Milestones

2H CY2020

JULY 2020

- Pilot study evaluating the intranasal route of delivery for drug candidates
- Nyrada Brain Injury Data published by premier US Military Health conference, US Military Health System Research Symposium
- Drug candidates successfully delivered by continuous intravenous injection, maintaining effective therapeutic levels in the brain, with no adverse effects observed

CY2021

FEB 2021

- Collaboration secured with WRAIR and UNSW Sydney

JUN 2021

- New, more potent analogue of Nyrada's brain injury candidate, (NYR-BI01)
- Pilot work to optimise PBBI / CCI models, drug formulation and delivery, and MRI scanning, (WRAIR & UNSW Sydney)

CY2022

MAR 2022

- New lead drug candidate NYR-BI02 selected for Phase I study

UPCOMING

- Brain injury drug candidate testing in preclinical model of stroke in Q2 CY2022
- Complete PBBI / CCI efficacy studies
- Phase I first in human study anticipated to commence second half of CY2022

Corporate Update

ASX:NYR

FY2021 Financial Summary

Highlights

- Cash position as at 31 December 2021 was $11.1M
- R&D Tax Incentive refund of $2.3M relating to the accrued FY2021 refund of $1.3M and received FY2020 refund of $1.0M
- R&D Tax Incentive refund of $1.3M received in January 2022, further boosting capital resources
- Nyrada is capitalised to fund the planned Phase I clinical trials for both lead programs, and enable further proof-of-concept studies

Strong Intellectual Property Position

- US Patent granted for Nyrada's PCSK9 inhibitor technology (expiry date 16 March 2038)
    - Provides composition of matter protection
- Corresponding European patent is in the final stages of examination
- PCT application filed in December 2021 for additional PCSK9 inhibitor compounds
- Provisional patent for Brain Injury Program anticipated to be filed in early Q2 CY2022

Key Metrics & Timing of Phase I Studies

Key Metrics	
Market capitalisation (as at 29 March 2022)	**$32.7M**
Share price (as at 29 March 2022)	**$0.21**
CDIs free float	**156,008,700**
Cash at bank 31 Dec 2021	**A$11.1M**
ASX listing	**January 16, 2020**

Pathway to Phase I Studies	
	*Expected to Commence**
Cholesterol-Lowering Program	2H CY2022
Brain Injury Program	2H CY2022

*Following completion of preclinical studies (safety pharmacology and toxicology)

Questions?

Brain Injury Solution Animation

Cholesterol-Lowering Animation

@nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com


Nyrada
inc
www.nyrada.com